These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 20379319)
1. Orbital mass as a presenting sign of acute leukemia. Sari A; Erkayhan G; Unal S; Adiguzel U Can J Ophthalmol; 2010 Apr; 45(2):188-9. PubMed ID: 20379319 [No Abstract] [Full Text] [Related]
2. FLAIE (fludarabine, cytarabine, idarubicin, and etoposide), a four drug induction chemotherapy for adult acute myeloid leukemia: A single center experience. Candoni A; Simeone E; Tiribelli M; Malagola M; Russo D; Fanin R Am J Hematol; 2009 Oct; 84(10):690-2. PubMed ID: 19731308 [No Abstract] [Full Text] [Related]
3. Association between the TP53 Arg72Pro polymorphism and clinical outcomes in acute myeloid leukemia. Bezerra MF; Coelho-Silva JL; Nascimento JC; Benicio MT; Rocha CR; Machado CG; Rego EM; Bezerra MA; Lucena-Araujo AR; Beltrão EI Haematologica; 2017 Feb; 102(2):e43-e46. PubMed ID: 27846614 [No Abstract] [Full Text] [Related]
4. Bilateral Acute Proptosis as Initial Manifestation of Acute Myeloid Leukemia. Huang YC; Wang SC; Chen SN; Jou JR Orbit; 2015; 34(5):248-52. PubMed ID: 26186043 [TBL] [Abstract][Full Text] [Related]
5. Remission induction therapy for adults with acute myelogenous leukemia: towards the ICE age? Bassan R; Barbui T Haematologica; 1995; 80(1):82-90. PubMed ID: 7758997 [TBL] [Abstract][Full Text] [Related]
6. Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) for the treatment of children with poor-prognosis acute leukemia: the Hacettepe experience. Tavil B; Aytac S; Balci YI; Unal S; Kuskonmaz B; Yetgin S; Gurgey A; Tuncer M; Gumruk F; Uckan D; Cetin M Pediatr Hematol Oncol; 2010 Oct; 27(7):517-28. PubMed ID: 20677923 [TBL] [Abstract][Full Text] [Related]
12. Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial results. Pigneux A; Perreau V; Jourdan E; Vey N; Dastugue N; Huguet F; Sotto JJ; Salmi LR; Ifrah N; Reiffers J Haematologica; 2007 Oct; 92(10):1327-34. PubMed ID: 18024370 [TBL] [Abstract][Full Text] [Related]
13. Idarubicin in combination with etoposide and cytarabine in adult acute non-lymphoblastic leukaemia (ANLL). Carella AM; Pungolino E; Piatti G; Giordano D; Cerri R; Risso M; Nati S Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():50-1. PubMed ID: 2713562 [No Abstract] [Full Text] [Related]
14. Acute megakaryoblastic leukemia in children and adolescents, excluding Down's syndrome: improved outcome with intensified induction treatment. Reinhardt D; Diekamp S; Langebrake C; Ritter J; Stary J; Dworzak M; Schrauder A; Zimmermann M; Fleischhack G; Ludwig WD; Harbott J; Creutzig U Leukemia; 2005 Aug; 19(8):1495-6. PubMed ID: 15920489 [No Abstract] [Full Text] [Related]
15. Acceleration of leukaemia with granulocyte colony-stimulating factor in a patient with aleukaemic leukaemia. Fata F; Myers P; Addeo J; Nawabi I Br J Hosp Med; 1997 Jul 9-Aug 19; 58(2-3):111-2. PubMed ID: 9349378 [No Abstract] [Full Text] [Related]
16. Results of treatment with an intensive combination induction regimen containing idarubicin in children with acute myeloblastic leukemia: preliminary report of the Argentine Group for Treatment of Acute Leukemia. Sackmann-Muriel F; Fernández-Barbieri MA; Santarelli MT; Matus-Ridley M; Rosso A; Negri-Aranguren P; Cerutti I; Gomel M; Kvicala R Semin Oncol; 1993 Dec; 20(6 Suppl 8):34-8. PubMed ID: 8290970 [TBL] [Abstract][Full Text] [Related]
17. Utility of myeloperoxidase stain in the differential diagnosis of leukemia cutis vs. hystiocitoid Sweet syndrome. Valerón-Almazán P; Bastida J; Vilar J; Santana N; Medina C; Carretero G Dermatol Online J; 2011 Apr; 17(4):11. PubMed ID: 21549086 [TBL] [Abstract][Full Text] [Related]
18. Blue toes and a new pair of shoes--challenges in diagnosis and treatment of acute myelogenous leukemia. Mar N; Gorgan MA; Dailey ME; Vredenburgh JJ Am J Hematol; 2013 Dec; 88(12):1090-3. PubMed ID: 23918652 [No Abstract] [Full Text] [Related]
19. Short course infusional idarubicin plus intermittent cytarabine and etoposide for refractory hematologic malignancies: clinical and preliminary pharmacological results. Bassan R; Chiodini B; Zucchetti M; Lerede T; Cornelli PE; Cortelazzo S; Barbui T Haematologica; 1998 Jan; 83(1):27-33. PubMed ID: 9542320 [TBL] [Abstract][Full Text] [Related]